Education only · not a recommendation of either topic

Side by side

BPC-157 vs TB-500

Why people compare these. Both appear in the same recovery-focused research conversations and are often mentioned together, which leads people to ask whether they are interchangeable. They are not: they come from different biological origins and are studied in different mechanisms.

Medically reviewed by Bernard Garcia, MD
What it is
BPC-157 A synthetic peptide of 15 amino acids whose sequence is described as derived from a protein fragment found in gastric juice.
TB-500 A synthetic fragment related to thymosin beta-4, a naturally occurring protein involved in cell movement and structure.
Research context
BPC-157 Discussed mainly in laboratory and animal studies of tendon, ligament, and gastrointestinal-lining tissue. Published human data is limited.
TB-500 Discussed in laboratory and animal studies of cell migration, tissue repair, and inflammation. Human evidence is limited to small early studies.
Research status
BPC-157 Preclinical (animal models) · limited human data
TB-500 Preclinical (animal models) · early human studies only
Typically discussed for
BPC-157 Soft-tissue and gut-lining recovery conversations
TB-500 Recovery, mobility, and tissue-repair conversations

How they differ

Origin. BPC-157’s sequence is described as derived from a gastric protein; TB-500 relates to thymosin beta-4, a protein found throughout the body. Different starting points, different proposed pathways.

Where the research sits. BPC-157 literature clusters around tendon, ligament, and gut-lining models. TB-500 literature clusters around cell-migration and general tissue-repair models. Neither has the kind of large, controlled human trials that would establish clinical benefit.

Regulatory status. Neither is an FDA-approved drug for any use. Both are subject to rules on research peptides that differ markedly between countries.

What that means for you. The question is not “which is better” but whether either topic is appropriate for your history at all — something only a licensed provider can assess after a confidential intake.

Questions for a provider

  • Is there any human evidence for the goal I have in mind, or is it all preclinical?
  • Given my history and medications, is either topic something you would even consider?
  • What would you want to rule out or test before discussing this further?
  • How would we know whether it was doing anything, and when would we stop?

Which is right for you?

Neither this page nor any website can answer that. The comparison exists so your conversation with a licensed provider starts from an informed place; the provider decides what, if anything, is appropriate after a confidential intake.

Discuss both with a provider

Free · about 10 minutes · reviewed by a licensed physician

General education · Not medical advice · Provider approval required